(20.2.2007) SEED Capital completes initial investments in the biotechnological company, 2cureX, a spin-out from Carlsberg Research Center.

2cureX is an innovative drug discovery company based on the novel and patented technology, ChemoCellomics™, which allows early identification of drug molecules directly in cells from cancer patients.The leading objective of 2cureX is to identify and develop In vivo efficacious lead candidates against colorectal cancer.

Please visit our portfolio description of 2cureX

Web: www.2curex.com

For further information, please contact.

Ole Bitsch-Jensen, Investment Manager

obj@seedcapital.dk

(published: 20 february 2007)